Cardiac Biomarkers: Case Studies and Clinical Correlations

✍ Scribed by Alan S. Maisel, Allan S. Jaffe (eds.)

• Publisher: Springer International Publishing
• Year: 2016
• Tongue: English
• Leaves: 368
• Edition: 1
• Category: Library

✦ Synopsis

This book covers ACS and Heart Failure, the chapters represent the most current, up to date and knowledgeable content on the topic available. It is written by the worlds most respected leaders in biomarkers, with a majority emphasis on what clinicians need to know.
The Editors and their contributors have provided algorithms, annotated case discussions and caveats. They cover biomarkers to predict risk of heart disease, biomarkers of cardiorenal disease , and conclude with a section on new and emerging biomarkers. It be genuinely helpful and practical to those in the field, including not just people working in the field, but nurses, doctors, etc who practice medicine in the clinic, the emergency department and the hospital.​

✦ Table of Contents

Front Matter....Pages i-xviii
Front Matter....Pages 1-1
Pre-analytical Factors and Analytical Issues Affecting Interpretation of Cardiovascular Biomarkers....Pages 3-15
Troponin Basics for Clinicians....Pages 17-29
Unique Aspects of High Sensitivity Assays: What Are They, Why Do We Need Them, and How Do We Use Them?....Pages 31-39
Evaluation of Patients Presenting with Chest Pain in the Emergency Department: Where Do Troponins Fit In?....Pages 41-55
Using Cardiac Troponins in Patients with Acute Myocardial Infarction....Pages 57-68
What Is a Type 2 Myocardial Infarction: How Is It Recognized and What Should One Do to Establish That Diagnosis?....Pages 69-78
Use of Cardiac Troponin in Patients with Heart Failure....Pages 79-91
Elevated cTn in Other Acute Situations Such as Atrial Fibrillation, Sepsis, Respiratory Failure, and Gastrointestinal Bleeding....Pages 93-109
Use of cTn for Detection of More Chronic Disease States....Pages 111-122
Use of High-Sensitive cTn Assays for the Evaluation of Patients Potentially at Risk for Cardiovascular Disease....Pages 123-134
Other Biomarkers in Acute Coronary Syndrome....Pages 135-143
Newer Lipid Markers: Apolipoprotein B, LDL Particle Concentration, and Triglyceride-Rich Lipoproteins – When Are They Needed?....Pages 145-158
Front Matter....Pages 159-159
Natriuretic Peptides: Physiology for the Clinician....Pages 161-172
Natriuretic Peptides: Basic Analytic Considerations....Pages 173-180
Natriuretic Peptide Use in Screening in the Community....Pages 181-193
Natriuretic Peptide Use in the Emergency Department....Pages 195-206
Heart Failure: Natriuretic Peptide Use in the Hospital....Pages 207-213
Natriuretic Peptide Guided Therapy in Outpatient Heart Failure Management....Pages 215-225
Caveats Using Natriuretic Peptide Levels....Pages 227-236
Gaps in Our Biomarker Armamentarium: What Novel Biomarkers Might Be Synergistic in Patients with Acute Disease....Pages 237-250
Front Matter....Pages 159-159
Biomarkers in Heart Failure: ST2....Pages 251-268
Biomarkers in Heart Failure: Procalcitonin....Pages 269-284
Novel Biomarkers in Heart Failure: Adrenomedullin and Proenkephalin....Pages 285-296
Biomarkers in Specific Disease States: Cardio-Oncology....Pages 297-315
Biomarkers of Sarcopenia and Mitochondrial Dysfunction....Pages 317-327
Biomarkers in Arrhythmias, Sudden Death, and Device Therapy....Pages 329-343
Biomarkers in Cardio-Renal Dysfunction....Pages 345-356
Biomarkers in Heart Failure with Preserved Ejection Fraction....Pages 357-365
Back Matter....Pages 367-370

✦ Subjects

Cardiology